9362 Federal Register / Vol. 87, No. 34 / Friday, February 18, 2022 / Notices 

This RFI is for planning purposes 

only and should not be construed as a 

policy, solicitation for applications, or 

as an obligation on the part of the 

Government to provide support for any 

ideas identified in response to it. AHRQ 

will use the information submitted in 

response to this RFI at its discretion and 

will not provide comments to any 

responder’s submission. However, 

responses to the RFI may be reflected in 

future solicitation(s) or policies. The 

information provided will be analyzed 

and may appear in reports. Respondents 

will not be identified in any published 

reports. Respondents are advised that 

the Government is under no obligation 

to acknowledge receipt of the 

information received or provide 

feedback to respondents with respect to 

any information submitted. No 

proprietary, classified, confidential, or 

sensitive information should be 

included in your response. The contents 

of all submissions will be made 

available to the public upon request. 

Materials submitted must be publicly 

available or able to be made public. 

Dated: February 15, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–03551 Filed 2–17–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

SIP22–004, Disability and Health Data 

Collaborative: Using Data to Promote the 

Health and Wellness of People with 

Disabilities. 

Date: May 3, 2022. 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman, Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107– 

B, Atlanta, Georgia 30341, Telephone: 

(770) 488–6511, Email: JRaman@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–03554 Filed 2–17–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—RFA–PS–22– 

001, Implementing Pre-Exposure 

Prophylaxis for HIV Prevention in 

Syringe Service Programs; RFA–PS– 

22–002, Implementation Research on 

Telehealth Strategies To Support 

Retention in Care and Treatment 

Among Antiretroviral Therapy (ART) 

Patients and Pre-Exposure Prophylaxis 

(PrEP) Clients and RFA–PS–22–004, 

Understanding HIV/STD Risk and 

Enhancing PrEP Implementation 

Messaging in a Diverse CommunityBased Sample of Gay, Bisexual, and 

Other Men Who Have Sex With Men in 

a Transformational Era; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Disease, Disability, 

and Injury Prevention and Control 

Special Emphasis Panel (SEP) RFA–PS– 

22–001, Implementing Pre-exposure 

Prophylaxis for HIV Prevention in 

Syringe Service Programs; RFA–PS–22– 

002, Implementation Research on 

Telehealth Strategies to support 

Retention in Care and Treatment among 

Antiretroviral Therapy (ART) Patients 

and Pre-exposure Prophylaxis (PrEP) 

Clients; and RFA–PS–22–004, 

Understanding HIV/STD Risk and 

Enhancing PrEP Implementation 

Messaging in a Diverse CommunityBased Sample of Gay, Bisexual, and 

Other Men Who Have Sex with Men in 

a Transformational Era. 

Date: March 30, 2022. 

Time: 10:00 a.m.–5:00 p.m. (EDT). 

Place: Teleconference. 

The meeting was published in the 

Federal Register on February 4, 2022, 

Volume 87, Number 24, page 6562– 

6563. 

The meeting is being amended to 

remove RFA–PS–22–002, 

Implementation Research on Telehealth 

Strategies to Support Retention in Care 

and Treatment among Antiretroviral 

Therapy (ART) Patients and Preexposure Prophylaxis (PrEP) Clients and 

should read as follows: 

RFA–PS–22–001, Implementing Preexposure Prophylaxis for HIV 

Prevention in Syringe Service Programs 

and RFA–PS–22–004, Understanding 

HIV/STD Risk and Enhancing PrEP 

Implementation Messaging in a Diverse 

Community-Based Sample of Gay, 

Bisexual, and Other Men Who Have Sex 

with Men in a Transformational Era. 

The meeting is closed to the public. 

For Further Information Contact: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, CDC, 1600 Clifton 

Road NE, Mailstop US8–1, Atlanta, 

Georgia 30329, Telephone: (404) 718– 

8833, Email: GAnderson@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–03555 Filed 2–17–22; 8:45 am] 

BILLING CODE 4163–18–P 


jspears on DSK121TN23PROD with NOTICES1